Dr Delphine Muriaux | Shining New Light on Human Immunodeficiency Virus Assembly Mechanisms

People living with human immunodeficiency virus (HIV) now have very effective treatment options to allow them to live long lives but the need for new and improved therapeutics remains. Dr Delphine Muriaux from Le Centre national de la recherche scientifique (CNRS) in Montpellier, France, researches HIV infection and replication utilising advanced state-of-the-art microscopy. This super-resolution imaging has led to new findings on the importance of the HIV-1 Gag proteins and the cellular host co-factor IRSp53, a membrane curving protein, and how they interact with host cell membranes.

Human Immunodeficiency Virus: Risks and Replication

Human immunodeficiency virus (HIV) is a pathogen that infects and destroys cells in the immune system. Because it is found in certain bodily fluids, HIV can be passed on through sex, sharing needles and pregnancy or breastfeeding. Initially, an infection may present with flu-like symptoms for a couple of weeks and then seemingly disappear for years. However, if left untreated, HIV eventually leads to acquired immune deficiency syndrome (AIDS), where the immune system becomes increasingly damaged and minor additional infections can prove severe or even fatal.

Diagnosing HIV can be achieved through a blood or saliva test and fortunately, there are now very effective treatments for those who are HIV positive. Antiretroviral drugs are taken every day to prevent the virus from replicating so that the immune system can repair itself. Thanks to these lifesaving therapeutics and other interventions, new HIV infections have been dropping since 1997, but there are still an estimated 37.7 million people living with the virus worldwide.

In order to continue to improve available therapeutics and quality of care for HIV patients, it is important to study the virus and all its complex activities. Dr Delphine Muriaux has built a ‘Membrane Domains and Viral Domains’ team of dedicated scientists to do just this at the Institut de Recherche en Infectiologie de Montpellier (IRIM). This institute sits within Le Centre national de la recherche scientifique (CNRS) in Montpellier, France.

The mechanisms by which HIV infects cells are extensively researched, but there remains much to discover about its molecular activities. The virus invades immune cells called CD4⁺ T helper cells, which are a type of white blood cell that help to activate other aspects of the immune system as well as suppress immune reactions where necessary. HIV can also infect types of white blood cells called macrophages and dendritic cells.

To enter a target host cell, a glycoprotein on the HIV particle binds to a receptor on the CD4⁺ cell. These two structures have a strong affinity (attraction) to each other. Once attached, a viral nucleocapsid containing its genetic material and certain enzymes enters the cell. These enzymes including reverse transcriptase, protease and viral integrase, are used to synthesise the new genome and integrate viral DNA into the host genome. From there, the host’s own DNA replication machinery is used to produce HIV proteins to be transported to the cytoplasm and assembled at the inner leaflet of the plasma membrane. The new HIV particle then assembles at the membrane and buds off to repeat the process, killing the host immune cell. This is why a patient’s immune system can be devastated by an uncontrolled HIV infection.

Shining New Light on Viral Assembly

Although this process of viral assembly has been understood for decades, the timeframe in which it occurs has only more recently been laid out. This is thanks to advancements in technology that allow scientists to observe biological activities on a molecular level, in real-time. Previous techniques were limited by the diffraction of light, which minimises the resolution possibilities for a microscope image. The diffraction barrier prevents a microscope from distinguishing between two objects that are less than half the wavelength of light used apart from each other. These objects can be singular molecules, which means that the molecular details of an HIV assembling within a host cell could not be viewed.

New solutions have overcome this barrier to enable super-resolution imaging of endless biological occurrences and structures. These visualisations often utilise microscopic molecules called fluorophores or fluorescent tags, which absorb specific wavelengths of light and emit a longer wavelength which is seen as colour. They can be designed to attach to specific biological structures so that different structures can be clearly observed in different colours. Super-resolution microscopy either involves selective deactivation of fluorophores or single-molecule detection and localisation.

In addition to the improvements in fluorescent tags, super-resolution microscopy has assisted new research from Dr Muriaux. After co-authoring a review on these advanced techniques and the results they have facilitated, she went on to utilise them in her own studies of the assembly of HIV in CD4 T cell plasma membrane. She believes that elucidating invasion and replication mechanisms on a never-before-seen molecular level will allow the entire infection process to be seen in a new light.

Dr Muriaux in the bioSafety level 3 laboratory at CEMIPAI CNRS Montpellier. Credit. Delphine Muriaux

Using Super-resolution Microscopy

One important aspect of HIV infection that Dr Muriaux could see in more detail was the activity of a protein called Gag. It is the main structural protein of HIV and other retroviruses – responsible for the assembly of viral particles. When HIV particles have replicated and budded from the host cell, the composition of their outer lipid membrane is very different from the plasma membrane of the host cell. It contains a notably higher concentration of types of phospholipids called phosphoinositides, including one major called phosphatidylinositol 4,5-bisphosphate lipid, or PI(4,5)P2 for short, as well as some cholesterol. The lipids (fats) in the HIV membrane are also highly ordered and densely packed.

These unusual differences led Dr Muriaux to question how the structures of an HIV particle such as Gag interact with a host plasma membrane to create such a specific environment. Is Gag targeted at existing lipid domains in the plasma membrane or does it somehow create these lipid compositions to help new viruses form? Dr Muriaux, with the help of Dr Cyril Favard from CNRS in Montpellier, France, and Drs Jakub Chojnacki and Christian Eggeling from the University of Oxford (UK), investigated these questions using super-resolution microscopy in living CD4⁺ T cells that were either infected with HIV or were not infected but were still expressing Gag. To visualise the movement of the lipids, they were tagged with fluorophores, as were the Gag proteins.

Tracking these different molecules in HIV-infected cells revealed that the virus immobilises PI(4,5)P2 and cholesterol but does allow sphingomyelins to move throughout the host cell. The cells that were not infected but expressed Gag showed the same characteristics, restricting the movement of the lipids at HIV assembly sites. This means that Dr Muriaux, her team and collaborators demonstrated that HIV-1 utilises its Gag proteins to selectively trap PI(4,5)P2 and cholesterol in host cells to produce their own specialised lipid membrane for particle assembly.

Illustration of HIV in blood

Facilitating Human Immunodeficiency Virus Budding

Dr Muriaux continued to investigate HIV Gag and plasma membrane deformation in a subsequent study. This time, she and her colleagues focused on membrane curvature, which is the bending of the membrane to accommodate the shape of organelles or biological processes. These can include endocytosis (taking an outside particle into a cell) and vesiculation (exiting the cell via formation, integration with the membrane and release of a vesicle). These mechanisms are important for HIV assembly and release. Previously, scientists thought that Gag was the sole driver of plasma membrane curvature for HIV particle formation, but Dr Muriaux has revealed that there is a more detailed mechanism.

She studied an I-BAR protein, IRSp53, which binds to membranes in a PI(4,5)P2-dependent manner with high affinity to generate a negative membrane curvature, meaning the membrane protrudes outwards. She chose IRSp53 due to her previous observations that it is implicated in a signalling pathway that promotes the release of HIV particles. These factors made it a prime candidate for being important in HIV Gag assembly and viral bud formation. She utilised single-molecule localisation microscopy to observe IRSp53 and its activities within cells.

T cells infected by HIV. Each dot is an HIV assembly platform at the cell surface of the infected CD4+ T lymphocytes. Each dot surrounding the cell is a single virus. Credit. MDVA research team, IRIM
Montpellier, France.

The results from these observations revealed that IRSp53 forms a complex (a bound structure) with Gag within cells, next to the cell plasma membrane. Therefore, through its membrane-bending abilities and interactions with Gag, IRSp53 is an essential factor for optimal HIV particle formation and replication. Proper and efficient HIV membrane curvature and complete assembly at the cell plasma membrane require IRSp53 and Gag to work together.

The importance of IRSp53 in viral budding was also demonstrated in a test whereby the gene that produces the IRSp53 protein was knocked down, meaning much less of the protein is produced. This resulted in a decrease in overall viral particle production and HIV budding was stopped halfway through the process. By discovering and documenting the replication mechanisms of HIV, scientists can better understand where and how to target them with drugs to prevent the virus from reproducing.

The research of Dr Muriaux, with her team at CNRS and collaboration with national and international academia laboratories as well as biotechnology companies, has allowed us to understand HIV infection in a new, much more detailed way. Her work is on track to inform the development of novel therapeutics for HIV and also pandemic viruses such as influenza viruses and coronaviruses.